Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Mo | Thiogenesis Therapeutics Corp: Thiogenesis receives patent in Europe | 2 | Stockwatch | ||
Mo | Thiogenesis Therapeutics, Corp.: Thiogenesis Announces Important Core Patent Allowed in Europe | 191 | Newsfile | San Diego, California--(Newsfile Corp. - November 4, 2024) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing novel thiol... ► Artikel lesen | |
28.09. | Thiogenesis Therapeutics Corp: Thiogenesis hires Triomphe for IR services | 2 | Stockwatch | ||
27.09. | Thiogenesis Therapeutics, Corp.: Thiogenesis Announces Investor Relations Engagement | 705 | Newsfile | San Diego, California--(Newsfile Corp. - September 27, 2024) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (Thiogenesis or the Company) a clinical-stage biotechnology company developing thiol-active... ► Artikel lesen | |
17.09. | Thiogenesis Therapeutics, Corp.: Thiogenesis Announces Presentation at 3rd Annual Leigh Syndrome Symposium | 393 | Newsfile | San Diego, California--(Newsfile Corp. - September 17, 2024) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing disulfides... ► Artikel lesen | |
20.08. | Thiogenesis Therapeutics Corp: Thiogenesis signs agreement with UCSD | 1 | Stockwatch | ||
20.08. | Thiogenesis Therapeutics, Corp.: Thiogenesis Announces Collaboration and Updates on Pediatric NASH Clinical Program | 195 | Newsfile | San Diego, California--(Newsfile Corp. - August 20, 2024) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing disulfides... ► Artikel lesen | |
18.07. | Thiogenesis Therapeutics Corp: Thiogenesis signs research deal for its Leigh compound | 2 | Stockwatch | ||
18.07. | Thiogenesis Therapeutics, Corp.: Thiogenesis Announces Leigh Syndrome Clinical Program | 330 | Newsfile | San Diego, California--(Newsfile Corp. - July 18, 2024) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing disulfides that... ► Artikel lesen | |
25.03. | Thiogenesis Therapeutics, Corp.: Thiogenesis Announces Acceptance of Clinical Trial Application - Part I in the EU for MELAS | 313 | Newsfile | San Diego, California--(Newsfile Corp. - March 25, 2024) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing disulfides... ► Artikel lesen | |
20.12.23 | Thiogenesis Therapeutics, Corp.: Thiogenesis Announces Closing of Final Tranche in $4.5 Million Non-Brokered Private Placement | 396 | Newsfile | San Diego, California--(Newsfile Corp. - December 20, 2023) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") is very pleased to announce that, further to its news release... ► Artikel lesen | |
17.12.23 | Thiogenesis Therapeutics, Corp.: Thiogenesis Announces Closing of Non-Brokered Private Placement of Common Shares and Insider Participation | 205 | Newsfile | San Diego, California--(Newsfile Corp. - December 18, 2023) - Further to its news release of November 20, 2023, Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") is very... ► Artikel lesen | |
04.12.23 | Thiogenesis Therapeutics, Corp.: Thiogenesis CEO Invited to Lead a Round Table Discussion at Influential Mitochondria Symposium | 604 | Newsfile | San Diego, California--(Newsfile Corp. - December 4, 2023) - Thiogenesis Therapeutics Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company that is developing sulfur-containing... ► Artikel lesen | |
27.11.23 | Thiogenesis Therapeutics, Corp.: Thiogenesis Announces Addition of Dr. Vince Stanton Jr. to Its Scientific Advisory Board | 544 | Newsfile | San Diego, California--(Newsfile Corp. - November 27, 2023) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing sulfur-containing... ► Artikel lesen | |
20.11.23 | Thiogenesis Therapeutics, Corp.: Thiogenesis Announces Non-Brokered Private Placement of Common Shares | 663 | Newsfile | San Diego, California--(Newsfile Corp. - November 20, 2023) - Thiogenesis Therapeutics Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") announced today that it will undertake a non-brokered private... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
EVOTEC | 8,100 | +13,37 % | Nach Minus 70%: Setzt die Evotec-Aktie damit jetzt zu einem sagenhaften Comeback an? | Nach einem beispiellosen Absturz im Jahr 2024 scheint die Aktie von Evotec nun in den Erholungsmodus umzuschalten. Aber wie nachhaltig sind die Kursgewinne des Biotech-Konzerns und wie hoch kann es... ► Artikel lesen | |
QIAGEN | 40,170 | +1,11 % | QIAGEN N.V.: QIAGEN erhält FDA-Zulassung für QIAstat-Dx Mini-Panel für eine präzisere ambulante Behandlung von Atemwegserkrankungen | QIAstat-Dx Respiratory Panel Mini erkennt die fünf relevantesten Erreger von Atemwegserkrankungen im ambulanten Bereich und hilft Ärzten dabei, präzise Behandlungsentscheidungen zu treffen // Mithilfe... ► Artikel lesen | |
ADMA BIOLOGICS | 19,120 | 0,00 % | ADMA Biologics, Inc. (NASDAQ:ADMA) Holdings Increased by Roman Butler Fullerton & Co. | ||
BIONTECH | 102,20 | -0,20 % | Biontech-Partner top in Q3: Pfizer übertrifft Erwartungen und hebt Jahresprognose an | © Foto: Foto: Nicolas Maeterlinck/ - BELGA/dpaPfizer hat starke Ergebnisse für das dritte Quartal präsentiert, die sowohl beim Umsatz als auch beim bereinigten Gewinn deutlich über den Analystenschätzungen... ► Artikel lesen | |
DISC MEDICINE | 58,19 | 0,00 % | Disc Medicine Inc: Disc Medicine Announces Successful End of Phase 2 Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP), Including Potential for Accelerated Approval | Alignment with the FDA across all proposed study parameters, providing a clear development path to registrationAgreement on proposed primary endpoint of average monthly time in sunlight during the... ► Artikel lesen | |
LONGBOARD PHARMACEUTICALS | 59,52 | 0,00 % | Longboard Pharmaceuticals, Inc.: Lundbeck to Acquire Longboard Pharmaceuticals in a Strategic Deal, Significantly Enhancing Its Neuroscience Pipeline | The proposed acquisition represents a significant step forward in Lundbeck's Focused Innovator strategy, adding a highly innovative and complementary product in late-stage development for Developmental... ► Artikel lesen | |
AVIDITY BIOSCIENCES | 44,820 | +6,46 % | Avidity Biosciences target held at $59 by Goldman Sachs | ||
SUMMIT THERAPEUTICS | 19,980 | 0,00 % | Summit Therapeutics Reports Operational Progress and Financial Results for the Third Quarter and Nine Months Ended September 30, 2024 | MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reported an update on its operational progress and financial results for the third quarter... ► Artikel lesen | |
HARMONY BIOSCIENCES | 33,075 | -0,14 % | Harmony Biosciences Reports Strong Third Quarter 2024 Financial Results And Highlights Catalyst-rich, Late-stage Pipeline Poised To Deliver One Or More New Launches Every Year Over Next Five Years | WAKIX (pitolisant) Net Revenue of $186.0 Million for Third Quarter 2024; Surpassed $2B in Cumulative Net Revenue in Less Than Five Years
On Track to Submit sNDA... ► Artikel lesen | |
ARCELLX | 86,46 | +0,99 % | Arcellx (ACLX) Surged in Q3. Here's Why | ||
BEAM THERAPEUTICS | 24,340 | +6,75 % | Beam Therapeutics Q3 2024 Earnings Preview | ||
DYNE THERAPEUTICS | 28,780 | 0,00 % | Dyne Therapeutics Reports Positive Data From Phase 1/2 DELIVER Trial Of DYNE-251 In DMD | WASHINGTON (dpa-AFX) - Tuesday, Dyne Therapeutics, Inc. (DYN) revealed new clinical findings from its Phase 1/2 DELIVER trial of DYNE-251 for patients with Duchenne muscular dystrophy also known... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 6,620 | 0,00 % | Peering Into Recursion Pharmaceuticals' Recent Short Interest | ||
IMMUNOVANT | 29,435 | 0,00 % | Immunovant Inc.: Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves' Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual Meeting | ||
TARSUS PHARMACEUTICALS | 46,240 | -1,83 % | Tarsus Pharmaceuticals stock hits 52-week high at $42.63 |